PTLA - ポルトラ・ファ―マシュ―ティカルズ (Portola Pharmaceuticals Inc.)

PTLAのニュース

   Portola Pharmaceuticals : Amendment to a previously filed SC 14D9 | MarketScreener  2020/06/30 16:44:10 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 … | June 30, 2020
   Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting  2020/05/18 20:02:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting…
   U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year  2020/05/14 12:00:00 Benzinga Feeds
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] through federal fiscal year 2021, for eligible Medicare beneficiaries treated in the inpatient hospital setting. Andexxa, first approved for use in the United States in May 2018 , received its NTAP designation effective October 1, 2018 . The proposed rule concerning the Hospital Inpatient Prospective Payment System and CMS Fiscal Year 2021 was released on Monday, May 11, 2020 ( https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-10122.pdf ), and will be published in the Federal Register on May 29, 2020 . Public comments on the proposal will be accepted through July 10, 2020 , and CMS is expected to release the final rule on or around September 1, 2020 . Finalization of the proposed continuation of NTAP status for Andexxa would go into effect on October 1 , 2020. "CMS' recommendation to extend NTAP designation aligns with our ongoing efforts and broader mission to expand access to Andexxa, the first and only FDA-approved reversal agent for the Factor Xa …
   Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update  2020/05/11 12:00:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to support public health efforts…
   ALEXION ACQUIRES PORTOLA PHARMACEUTICALS FOR $1.4 BILLION  2020/05/05 20:54:50 Medium
Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded in 2003, Portola is based in South San Francisco and…
   Portola Pharmaceuticals : Amendment to a previously filed SC 14D9 | MarketScreener  2020/06/30 16:44:10 MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 … | June 30, 2020
   Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting  2020/05/18 20:02:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting…
   U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year  2020/05/14 12:00:00 Benzinga Feeds
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] through federal fiscal year 2021, for eligible Medicare beneficiaries treated in the inpatient hospital setting. Andexxa, first approved for use in the United States in May 2018 , received its NTAP designation effective October 1, 2018 . The proposed rule concerning the Hospital Inpatient Prospective Payment System and CMS Fiscal Year 2021 was released on Monday, May 11, 2020 ( https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-10122.pdf ), and will be published in the Federal Register on May 29, 2020 . Public comments on the proposal will be accepted through July 10, 2020 , and CMS is expected to release the final rule on or around September 1, 2020 . Finalization of the proposed continuation of NTAP status for Andexxa would go into effect on October 1 , 2020. "CMS' recommendation to extend NTAP designation aligns with our ongoing efforts and broader mission to expand access to Andexxa, the first and only FDA-approved reversal agent for the Factor Xa …
   Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update  2020/05/11 12:00:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to support public health efforts…
   ALEXION ACQUIRES PORTOLA PHARMACEUTICALS FOR $1.4 BILLION  2020/05/05 20:54:50 Medium
Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded in 2003, Portola is based in South San Francisco and…
   Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting  2020/05/18 20:02:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting…
   U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year  2020/05/14 12:00:00 Benzinga Feeds
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA ) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] through federal fiscal year 2021, for eligible Medicare beneficiaries treated in the inpatient hospital setting. Andexxa, first approved for use in the United States in May 2018 , received its NTAP designation effective October 1, 2018 . The proposed rule concerning the Hospital Inpatient Prospective Payment System and CMS Fiscal Year 2021 was released on Monday, May 11, 2020 ( https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-10122.pdf ), and will be published in the Federal Register on May 29, 2020 . Public comments on the proposal will be accepted through July 10, 2020 , and CMS is expected to release the final rule on or around September 1, 2020 . Finalization of the proposed continuation of NTAP status for Andexxa would go into effect on October 1 , 2020. "CMS' recommendation to extend NTAP designation aligns with our ongoing efforts and broader mission to expand access to Andexxa, the first and only FDA-approved reversal agent for the Factor Xa …
   Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update  2020/05/11 12:00:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to support public health efforts…
   ALEXION ACQUIRES PORTOLA PHARMACEUTICALS FOR $1.4 BILLION  2020/05/05 20:54:50 Medium
Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded in 2003, Portola is based in South San Francisco and…
   Alexion to buy Portola Pharma for $1.4B  2020/05/05 16:22:34 Fox Business
Alexion will pay $18 per share for Portola, which closed at $7.76 per share on Monday.

calendar